Devonian Health Group Reports its Fourth Quarter and Annual 2025 Financial Results and Appointment of a New Board Member
Executive Summary
- Devonian Health Group reported FY 2025 net loss of C$6 million (C$0.041 per share), widening from a C$1.83 million loss YoY, driven by a C$4.6 million goodwill impairment and IP write‑down.
- Distribution revenues fell 87% in Q4 to C$1.3 million due to the expiry of the Dexlansoprazole distribution agreement, though FY 2025 revenue rose 22% YoY to C$23.6 million.
- The company is now debt‑free with C$7 million cash on hand and appointed Pierre Labbé, CPA, as a new board director; Jean Forcione resigned.
Key Details
- Financial Results – Q4 2025
- Distribution revenues: C$1.3 M, down 87% YoY (loss of Dexlansoprazole agreement).
-
Net loss: C$0.375 M (‑C$0.003 per share) vs. net income of C$0.75 M a year earlier.
-
Financial Results – FY 2025
- Distribution revenues: C$23.6 M, up 22% YoY; Dexlansoprazole accounted for 93% of revenue.
- R&D expenses: C$2 M, +55.8% YoY (phase 2/3 Thykamine™ pediatric atopic dermatitis study and pre‑clinical work).
- Net loss: C$6 M (‑C$0.041 per share) vs. C$1.83 M loss a year earlier.
-
Impairments: goodwill C$4.6 M, IP C$0.2 M (both linked to Altius distribution business).
-
Liquidity & Capital Structure
- Debt‑free after repaying long‑term debt of C$2.2 M during FY 2025.
-
Cash & cash equivalents: C$7 M as of July 31, 2025 (down from C$9.9 M at fiscal start).
-
Business Highlights
- Completed pre‑clinical studies exploring new Thykamine™ indications (MASH, fibrosis).
- Ongoing Phase 2/3 trial of Thykamine™ in pediatric mild‑to‑moderate atopic dermatitis.
-
Secured additional patent protection for Thykamine™ mechanisms and therapeutic uses.
-
Board Appointment
- Pierre Labbé, CPA – appointed as Director; brings >30 years financial leadership (current EVP Finance at Fonds QScale S.E.C., former CFO of IMV Inc., LeddarTech Inc., Medicago Inc.).
-
Jean Forcione resigned effective Sept 30, 2025.
-
Distribution Agreements
- Continued distribution of Pantoprazole Magnesium and Cléo‑35 through Altius until April 2026.
Notable Quotes
“Our year‑end results reflect a company that is financially disciplined, debt‑free, and strategically positioned for the next phase of value creation… we are intensifying our efforts to advance Thykamine™’s added‑value programs in the fibro‑inflammatory space.” – Dr. André Boulet, Chairman & CEO
“The Devonian’s Board of Directors is extremely pleased to be welcoming Mr. Pierre Labbé as director of the Corporation.” – Dr. André P. Boulet, President & CEO